Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07117760 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Name: Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer — clinical trial record (NCT07117760)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorFirst Affiliated Hospital of Fujian Medical University

Started2025-04-22

View on ClinicalTrials.gov ↗

Amendment history

2026-04-27

Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v1

Trial statusRecruiting→Active, Not Recruiting

Enrollment targetestimated 20→confirmed 16

Study sitesdetails revised at 1 of 1 site

2025-08-05

Original filing

First Affiliated Hospital of Fujian Medical University

56 trials monitored

See all monitored trials

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 225Ac-labeled LNC1011 for treating patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Trial Details

NCT Number	NCT07117760
Lead Sponsor	First Affiliated Hospital of Fujian Medical University
Conditions	Prostate Cancer
Enrollment	16 participants
Start Date	2025-04-22
Primary Completion	2027-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-29